000			01404 a2200361 4500
005			20250517011503.0
264		0	_c20160310
008			201603s 0 0 eng d
022			_a2210-741X
024	7		_a10.1016/j.clinre.2014.11.005 _2doi
040			_aNLM _beng _cNLM
100	1		_aDai, Xing-Bin
245	0	0	_aReactivation of hepatitis B virus 40 months after discontinuation of rituximab maintenance treatment and 5 months after cessation of entecavir administration. _h[electronic resource]
260			_bClinics and research in hepatology and gastroenterology _cJun 2015
300			_ae39-40 p. _bdigital
500			_aPublication Type: Case Reports; Letter
650	0	4	_aAged, 80 and over
650	0	4	_aAntineoplastic Agents _xadministration & dosage
650	0	4	_aAntiviral Agents _xadministration & dosage
650	0	4	_aFatal Outcome
650	0	4	_aFemale
650	0	4	_aGuanine _xadverse effects
650	0	4	_aHepatitis B _xetiology
650	0	4	_aHepatitis B virus _xdrug effects
650	0	4	_aHumans
650	0	4	_aRituximab _xadministration & dosage
650	0	4	_aTime Factors
650	0	4	_aWithholding Treatment
700	1		_aSun, Xue-Mei
700	1		_aZhu, Xue-Jun
773	0		_tClinics and research in hepatology and gastroenterology _gvol. 39 _gno. 3 _gp. e39-40
856	4	0	_uhttps://doi.org/10.1016/j.clinre.2014.11.005 _zAvailable from publisher's website
999			_c24503030 _d24503030